Flexus Biosciences

Small-molecule cancer immunotherapies (IDO/TDO inhibitors) that target regulatory T cells.

placeSan Carlos, California, United States calendar_todayFounded 2013 groups14 employees language flexusbio.com

Registered entities

Innovation

5 patent families (4 granted) — focus: Chemistry & metallurgy, Human necessities; filing pace slowing. Cited 1,504 times.

YearFilings
20151
20163
20175
20184
20193
20202
20213
20222
20231
20242
20251

Investor mix

4 investors on record.

Investor typeCountShare
Venture capital375%
Other / undisclosed125%
Coming soon